KPTI - Karyopharm Therapeutics Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.
IPO Date: November 6, 2013
Sector: Healthcare
Industry: Drug Manufacturers
Market Cap: $14.63M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.40 | 3.87%
Avg Daily Range (30 D): $0.09 | 6.22%
Avg Daily Range (90 D): $0.29 | 5.79%
Institutional Daily Volume
Avg Daily Volume: .99M
Avg Daily Volume (30 D): 1.36M
Avg Daily Volume (90 D): 1.21M
Trade Size
Avg Trade Size (Sh.): 149
Avg Trade Size (Sh.) (30 D): 216
Avg Trade Size (Sh.) (90 D): 158
Institutional Trades
Total Institutional Trades: 2,389
Avg Institutional Trade: $1.65M
Avg Institutional Trade (30 D): $.68M
Avg Institutional Trade (90 D): $2.08M
Avg Institutional Trade Volume: .02M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.88M
Avg Closing Trade (30 D): $.86M
Avg Closing Trade (90 D): $2.48M
Avg Closing Volume: 19.27K
 
News
Sep 3, 2026 @ 5:00 PM
Advanced Endometrial Cancer Clinical Trial Pipelin...
Source: Delveinsight
Aug 4, 2026 @ 8:51 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: Pomerantz Llp
Jun 14, 2026 @ 10:30 AM
Menarini Group Reports Data from the Phase 3 SENTR...
Source: Na
Mar 1, 2025 @ 1:45 PM
International Myeloma Foundation (IMF) Celebrates ...
Source: International Myeloma Foundation
Nov 25, 2024 @ 4:00 PM
Glioblastoma Multiforme Treatment Market Size to R...
Source: Precedence Research
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-14.16 $-2.32 $-1.02
Diluted EPS $-14.38 $-2.32 $-1.24
Revenue $146.62M $33.43M $35.07M
Gross Profit
Net Income / Loss $-224.74M $-67.02M $-22.39M
Operating Income / Loss $-82.35M $-22.53M $-26.76M
Cost of Revenue
Net Cash Flow $16.22M $-35.87M $30.28M
PE Ratio    
Splits
Feb 26, 2025 1:15